Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Analysts give Alector a consensus "Hold" rating from eight firms (2 sell, 3 hold, 3 buy) with an average 12‑month price target of $3.63, and recent moves include upgrades from BTIG and Cantor Fitzgerald and downgrades from Weiss and Wall Street Zen.
• Alector's latest quarter beat estimates—EPS loss of ($0.34) vs. consensus ($0.39) and revenue $6.24M vs. $1.78M—but the company remains deeply unprofitable with a negative net margin of 679% and analysts expect about -0.88 EPS for the year.
• Shares opened at $2.51 with a market cap of $278.7M and a 52‑week range of $0.97–$3.40, and institutional investors hold about 85.83% of the stock.

Shares of Alector, Inc. (NASDAQ:ALEC - Get Free Report) have earned an average rating of "Hold" from the eight research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $3.6250.

Several equities research analysts have issued reports on ALEC shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Alector in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Alector from a "hold" rating to a "sell" rating in a report on Sunday, March 1st. BTIG Research raised shares of Alector from a "neutral" rating to a "buy" rating and set a $6.00 target price on the stock in a report on Tuesday, March 10th. Cantor Fitzgerald raised shares of Alector from a "neutral" rating to an "overweight" rating in a report on Wednesday, April 15th. Finally, Morgan Stanley reaffirmed an "underweight" rating and issued a $2.00 target price on shares of Alector in a report on Monday.

Institutional Investors Weigh In On Alector

Large investors have recently made changes to their positions in the company. Lexington Partners L.P. bought a new stake in shares of Alector in the 3rd quarter worth about $30,000. Pinegrove Venture Partners LLC bought a new stake in shares of Alector in the 3rd quarter worth about $30,000. Belvedere Trading LLC bought a new stake in shares of Alector in the 3rd quarter worth about $31,000. Savant Capital LLC bought a new stake in shares of Alector in the 3rd quarter worth about $35,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of Alector in the 3rd quarter worth about $37,000. Institutional investors own 85.83% of the company's stock.

Alector Trading Up 6.4%

Shares of Alector stock opened at $2.51 on Tuesday. The firm has a market capitalization of $278.69 million, a PE ratio of -1.81 and a beta of 0.64. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.83 and a quick ratio of 3.83. The company's fifty day moving average price is $2.29 and its two-hundred day moving average price is $1.88. Alector has a 52-week low of $0.97 and a 52-week high of $3.40.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. The firm had revenue of $6.24 million for the quarter, compared to analyst estimates of $1.78 million. Alector had a negative net margin of 679.16% and a negative return on equity of 224.96%. On average, analysts expect that Alector will post -0.88 EPS for the current year.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector's approach aims to harness the body's natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer's disease and frontotemporal dementia.

The company's pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer's disease studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.